The expression level of ARIH2 may serve as a promising biomarker for the diagnosis and prognosis of HCC, as well as a potential drug target, which holds great significance for the development of targeted therapy for HCC. The gene discussed is ARIH2; the disease is hepatocellular carcinoma.